MedTrace Logo

Trial on Treatment With Inhaled Furosemide of Preterm and Term Neonates With Transient Tachypnoea

NCT01407848 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-09-23

No results posted yet for this study

Summary

In this study we will prospectively analyze the benefit of inhaled furosemide for preterm and term neonates with Transient Tachypnoea.

Conditions

  • Transient Tachypnoea of the Newborn

Interventions

DRUG

Furosemide

Patients received nebulised Furosemide iv solution 1 mg/kg (4x/d) for max.3 consecutive days.

DRUG

Saline 0,9%

nebulised 0,9% saline 4x/d for max.3 days

Sponsors & Collaborators

  • University of Cologne

    lead OTHER

Principal Investigators

  • Bernhard Roth, Prof. Dr. · University Cologne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Hours
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01407848 on ClinicalTrials.gov